Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. (ASCO 2023) - Apr 27, 2023 - Abstract #2564; Pres time: Jun 3, 2023; 08:00 AM - 11:00 AM; Location: Available On Demand; Poster Bd # 406; "The combination of high subcutaneous doses or intra-tumoral administration of lefitolimod in combination with ipilimumab is safe and well tolerated in patients with advanced cancers, with preliminary antitumor activity observed. Clinical trial information: NCT0266877."
Clinical • Metastases • P1 data • Dermatology • Fatigue • Oncology • Pruritus • Solid Tumor • CD8
|
|
Mirella Nardo; Matthew Reilley; Amadeo Biter; JoAnn Lim; Stacie A. Bean; Ly Minh Nguyen; Priya Bhosale; Casey Ager; Coline A Couillault; Sarina A. Piha-Paul; Siqing Fu; Apostolia Maria Tsimberidou; Timothy A. Yap; Aung Naing; Jordi Rodon Ahnert; Vivek Subbiah; Daniel D. Karp; Michael A. Curran; David S. Hong
|